These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15856324

  • 1. Cyclosporin A absorption profiles in children with nephrotic syndrome.
    Nozu K, Iijima K, Sakaeda T, Okumura K, Nakanishi K, Yoshikawa N, Honda M, Ikeda M, Matsuo M.
    Pediatr Nephrol; 2005 Jul; 20(7):910-3. PubMed ID: 15856324
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
    Vavić N, Ignjatović L, Drasković B, Hrvacević R, Kovacević Z, Paunić Z.
    Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
    [Abstract] [Full Text] [Related]

  • 3. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F.
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [Abstract] [Full Text] [Related]

  • 4. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R.
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [Abstract] [Full Text] [Related]

  • 5. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
    Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
    [Abstract] [Full Text] [Related]

  • 6. Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.
    Ushijima K, Uemura O, Yamada T.
    Eur J Pediatr; 2012 Apr; 171(4):663-8. PubMed ID: 22116269
    [Abstract] [Full Text] [Related]

  • 7. C1-C2 point monitoring of low-dose cyclosporin a given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome.
    Nakahata T, Tanaka H, Tsugawa K, Kudo M, Suzuki K, Ito E, Waga S.
    Clin Nephrol; 2005 Oct; 64(4):258-63. PubMed ID: 16240896
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.
    Hibino S, Nagai T, Yamakawa S, Ito H, Tanaka K, Uemura O.
    Clin Exp Nephrol; 2017 Feb; 21(1):152-158. PubMed ID: 27105859
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, Yacoub MH.
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
    Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A.
    Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
    [Abstract] [Full Text] [Related]

  • 11. [Study of the correlation between drug exposure and blood concentration during cyclosporine microemulsion absorption phase in Chinese adult liver transplant recipients].
    Chen G, He Y, Chen YC, Wang HZ, Chen JH, Dong JH.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):328-30. PubMed ID: 15225421
    [Abstract] [Full Text] [Related]

  • 12. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation.
    Levy GA.
    BioDrugs; 2001 Jun; 15(5):279-90. PubMed ID: 11437692
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic durg monitoring of cyclosporin using area under the curve in nephrotic syndrome.
    Gaies E, Ben Sassi M, Charfi R, Salouage I, Jebabli N, ElJebari H, Klouz A, Daghfous R, Trabelsi S.
    Tunis Med; 2019 Feb; 97(2):360-364. PubMed ID: 31539095
    [Abstract] [Full Text] [Related]

  • 14. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
    Mahalati K, Belitsky P, Sketris I, West K, Panek R.
    Transplantation; 1999 Jul 15; 68(1):55-62. PubMed ID: 10428267
    [Abstract] [Full Text] [Related]

  • 15. Suitable whole blood levels 2 hours after neoral in liver transplant patients: experiences at a single center.
    Kim KH, Lee SG, Lee YJ, Park KM, Hwang S, Ahn CS, Moon DB, Ha TY, Song KW, Kim DS, Jung DH, Kim BS, Moon KM, Lee HJ, Park JI, Ryu JH.
    Transplant Proc; 2006 Nov 15; 38(9):2971-3. PubMed ID: 17112877
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic drug monitoring of cyclosporine MEPC (Neoral) therapy for interstitial pneumonia].
    Inoue T, Tanaka E, Kato T, Sakuramoto M, Minakuchi M, Maeda Y, Maniwa K, Terada K, Taguchi Y.
    Nihon Kokyuki Gakkai Zasshi; 2004 Feb 15; 42(2):153-7. PubMed ID: 15007915
    [Abstract] [Full Text] [Related]

  • 17. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients.
    Kelles A, Herman J, Tjandra-Maga TB, Van Damme-Lombaerts R.
    Pediatr Transplant; 1999 Nov 15; 3(4):282-7. PubMed ID: 10562972
    [Abstract] [Full Text] [Related]

  • 18. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients.
    Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P.
    Transplantation; 1998 Dec 27; 66(12):1621-7. PubMed ID: 9884249
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome.
    Henriques Ldos S, Matos Fde M, Vaisbich MH.
    Clinics (Sao Paulo); 2012 Oct 27; 67(10):1197-202. PubMed ID: 23070347
    [Abstract] [Full Text] [Related]

  • 20. Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.
    Kokuhu T, Fukushima K, Ushigome H, Yoshimura N, Sugioka N.
    Int J Med Sci; 2013 Oct 27; 10(12):1665-73. PubMed ID: 24151438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.